A father with metastatic kidney cancer embraces moments with his 3-year-old son while pondering how he'll be remembered.

by Adam P. Stern

Medical oncologist and lung cancer expert Roy S. Herbst discusses early data on drugs that target a mutated form of the KRAS protein.

by Anna Azvolinsky

Patient advocates have become a vital part of the San Antonio Breast Cancer Symposium. Opportunities for advocates continue to multiply.

by Marci A. Landsmann

Following the approval of the first immunotherapy for breast cancer by the U.S. Food and Drug Administration in March 2019, experts at the San Antonio Breast Cancer Symposium discussed avenues for further development.

by Marci A. Landsmann

Compared with intravenous paclitaxel, the oral form of the chemotherapy drug was associated with improved tumor shrinkage in metastatic breast cancer patients.

by Ashley P. Taylor

Studies presented at the San Antonio Breast Cancer Symposium show additional treatment options.

by Marci A. Landsmann

Patients with advanced cancer often go to rehabilitation facilities after a hospital stay in hopes of gaining the strength for further treatment, but the majority do not go on to receive additional cancer therapy, a study reports.

by Ashley P. Taylor

Immune checkpoint inhibitors can be effective treatments for elderly people with some types of advanced cancer, but more information is needed on their risks and benefits in this group.

by Emma Yasinski

Medical oncologist Leisha A. Emens discusses the significance of the first U.S. Food and Drug Administration approval of an immunotherapy treatment for breast cancer.

by Anna Azvolinsky

The multiple tumors in patients with metastatic disease share key genetic traits, a sequencing study shows.

by Anna Azvolinsky